ストックスクリーナーアプリを入手
16.07
0.88%
0.14
アフターアワーズ：
16.06
-0.01
-0.06%
前日終値:
$15.93
開ける：
$16
24時間の取引高:
8.36M
Relative Volume:
0.81
時価総額：
$18.71B
収益：
$14.57B
当期純損益:
$-296.50M
株価収益率:
-62.05
EPS:
-0.259
ネットキャッシュフロー:
$1.64B
1週間 パフォーマンス:
+4.55%
1か月 パフォーマンス:
-3.48%
6か月 パフォーマンス:
+31.29%
1年 パフォーマンス:
+80.76%
1日の値動き範囲:
$15.96
$16.39
1週間の範囲:
$15.07
$16.39
52週間の値動き範囲:
$8.625
$17.53
Viatris Inc Stock (VTRS) Company Profile
Compare VTRS vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
16.07 | 18.55B | 14.57B | -296.50M | 1.64B | -0.259 |
TAK
Takeda Pharmaceutical Co Adr
|
15.65 | 49.67B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.27 | 40.68B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.62 | 39.85B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.82 | 32.77B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
543.39 | 23.34B | 3.17B | 1.29B | 1.01B | 27.09 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-09 | アップグレード | UBS | Neutral → Buy |
| 2026-01-16 | アップグレード | Argus | Hold → Buy |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-10-15 | 開始されました | Truist | Buy |
| 2025-06-06 | 開始されました | Goldman | Neutral |
| 2024-07-19 | 再開されました | Jefferies | Buy |
| 2023-10-23 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-06-23 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2023-04-24 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2023-02-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-10 | アップグレード | UBS | Sell → Neutral |
| 2022-11-08 | アップグレード | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 再開されました | Jefferies | Hold |
| 2022-06-14 | 開始されました | UBS | Sell |
| 2022-05-10 | ダウングレード | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 開始されました | Citigroup | Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2021-03-08 | ダウングレード | Goldman | Buy → Neutral |
| 2021-03-02 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-02-26 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 開始されました | Argus | Hold |
| 2020-12-14 | 開始されました | Bernstein | Mkt Perform |
すべてを表示
Viatris Inc (VTRS) 最新ニュース
Form 144 Viatris Inc For: 25 June By Investing.com - Investing.com Canada
Viatris (VTRS) Rule 144 notice lists 49,715 vested shares and other entries - Stock Titan
How Viatris’ €650 Million Eurobond Issue (VTRS) Has Changed Its Investment Story - simplywall.st
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Soared 54%: Time To Be More Careful (Rating Downgrade) (NASDAQ:VTRS) - Seeking Alpha
Are Investors Undervaluing Viatris (VTRS) Right Now? - Yahoo Finance
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
Viatris Inc. (VTRS) Investor Outlook: Is The 15.89% Potential Upside Worth The Risk? - DirectorsTalk Interviews
How Is Viatris’ Stock Performance Compared to Other Healthcare Stocks? - Barchart.com
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Viatris Completes €650 Million 4.250% Senior Notes Due 2033 to Refinance 2026 Debt - TradingView
Viatris (NASDAQ: VTRS) issues €650M 4.25% notes to help refinance 2026 debt - Stock Titan
(VTRS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
XS332542958 Bond Price and Chart — FWB:XS332542958 - TradingView
Viatris Inc (VTRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Viatris Inc (VTRS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Viatris Inc (VTRS) Institutional Confidence - TradingKey
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Viatris Recognized as One of the 2026 Best Workplaces™ in Canada - Yahoo Finance
XS332542958 Bond Analysis — Key Metrics - TradingView
Viatris launches €650M 4.250% senior notes due 2033 offering - TradingView
Viatris (VTRS) prices €650M 4.250% senior notes maturing 2033 - Stock Titan
Viatris (VTRS) sells €650M 4.25% senior notes to refinance 2026 debt - Stock Titan
Euro Bond Sale Might Change The Case For Investing In Viatris (VTRS) - simplywall.st
Viatris Inc. (VTRS) Stock Analysis: Navigating Growth Prospects with an 8.09% Potential Upside - DirectorsTalk Interviews
Viatris (VTRS) Stock And The 58% Undervaluation Debate After A Strong Year Of Returns - Yahoo Finance
Viatris Euro Debt Raise Reshapes Capital Structure And Valuation Story - Yahoo Finance
Viatris (VTRS) Q1 2026 Earnings Call Transcript - Fortune
Viatris Inc. stock rises Friday, outperforms market - MarketWatch
[424B5] Viatris Inc Prospectus Supplement (Debt Securities) - Stock Titan
A Look at Viatris Inc (VTRS) After 3.4% Gain -- GF Value $11.01 vs Price $16.31 - GuruFocus
VTRS News | VIATRIS INC (NASDAQ:VTRS) - ChartMill
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
Viatris Inc. (VTRS) Stock Analysis: Exploring a 13.70% Potential Upside with a Strong Dividend Yield - DirectorsTalk Interviews
Viatris (VTRS) Holds Steady Near Support Amid Flat Trading SessionRSI Overbought Alerts - newsline.com
Liquidity Mapping Around (VTRS) Price Events - Stock Traders Daily
FDA accepts Viatris' NDA for fast-acting non-opioid pain therapy - MSN
Investors brace for Viatris earnings as CFO departure looms By Investing.com - Investing.com Nigeria
Here's Why Viatris (VTRS) is a Strong Value Stock - Yahoo Finance
Salesforce : Agentforce Life Sciences Selected by Viatris as Its Global Customer Engagement Platform - marketscreener.com
Salesforce Agentforce Life Sciences Selected by Viatris as Its Global Customer Engagement Platform - Salesforce
Viatris Inc. stock falls Monday, underperforms market - MarketWatch
Viatris Inc. (VTRS) Stock Analysis: Exploring An 11% Potential Upside Amid Mixed Metrics - DirectorsTalk Interviews
Does FDA Review of Fast-Acting Meloxicam Shift Viatris’ (VTRS) Non-Opioid Pain Strategy? - simplywall.st
Viatris Top Brass Sued by Investor Over India Facility Problems - Bloomberg Law News
Argus Raises Viatris Price Target to $18 From $15 - Moomoo
Why (VTRS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Analyst Report Highlights Viatris Inc’s Strategic Positioning Amid Generic Drug CompetitionLow Estimate Range - newsline.com
Viatris (VTRS) Under Pressure: Support Levels Tested After 1.5% DeclineVolatility Smile - newsline.com
Tacrolimus Market Research Report 2026: Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2035 - GlobeNewswire Inc.
Viatris Inc (VTRS) 財務データ
収益
当期純利益
現金流量
EPS
1.13%
4.02%
大文字化:
|
ボリューム (24 時間):